C022: Eculizumab Biosimilar Stable Cell Line (CHO)
The Eculizumab biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.
C022P: Eculizumab Biosimilar, Human C5 Monoclonal Antibody
Recombinant Humanized IgG2/4 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody Eculizumab biosimilar specifically binds to the human C5, the terminal complement component 5.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays.